Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practice Relevance as the North Star: A Message From the Editor.

The primary care companion for CNS disorders·2026
Same author

Standard Versus Enhanced Measurement-Based Care Effectiveness for Depression (EMBED): Protocol for a Cluster Randomized Implementation-Effectiveness Trial.

Cureus·2025
Same author

Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms.

Neuropsychopharmacology reports·2024
Same author

A Retrospective Cross-Sectional Analysis of the Humanistic and Economic Burden of Bipolar I Disorder.

Clinical therapeutics·2024
Same author

The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis.

Advances in therapy·2024
Same author

The PCC Is 25 Years Strong: A Message From the Editor.

The primary care companion for CNS disorders·2023

Related Experiment Video

Updated: Jun 5, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Pharmacologic therapy for fibromyalgia.

Larry Culpepper1

  • 1Department of Family Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA.

The Journal of Clinical Psychiatry
|December 31, 2010
PubMed
Summary
This summary is machine-generated.

Pharmacologic therapy offers significant fibromyalgia symptom relief and functional improvement when tailored to individual patient needs. Comprehensive evaluation guides personalized treatment for pain, sleep, and mood disorders.

More Related Videos

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Related Experiment Videos

Last Updated: Jun 5, 2026

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain
07:19

Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

Area of Science:

  • Rheumatology
  • Pharmacology
  • Clinical Medicine

Background:

  • Nonpharmacologic strategies aid fibromyalgia diagnosis acceptance.
  • Pharmacologic therapy provides additional symptom relief and functional improvement.
  • Fibromyalgia management requires a multifaceted approach.

Purpose of the Study:

  • To outline the principles of individualized pharmacologic therapy for fibromyalgia.
  • To emphasize the importance of comprehensive patient evaluation in treatment selection.
  • To guide the selection of pharmacologic treatments based on specific patient symptoms and preferences.

Main Methods:

  • Individualized pharmacologic therapy selection.
  • Comprehensive patient evaluation.
  • Continued assessment of symptoms and treatment response.

Main Results:

  • Pharmacologic therapy can significantly improve fibromyalgia symptoms.
  • Individualized treatment leads to better patient outcomes.
  • Addressing pain, sleep dysfunction, and mood disorders is crucial.

Conclusions:

  • Personalized pharmacologic treatment is essential for effective fibromyalgia management.
  • Therapy selection should consider the 'fibromyalgia triad' (pain, sleep, mood) and patient-specific factors.
  • Ongoing assessment ensures optimal treatment response and patient functioning.